NCT06899061 2026-03-03
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
AstraZeneca
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT06787131 2025-12-05
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
Lomond Therapeutics Holdings, Inc.
Phase 1 Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05602597 2024-03-06
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Hutchmed
Phase 1 Completed
NCT05930119 2023-09-06
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
Hutchmed
Phase 1 Completed
NCT05571787 2023-02-23
HMPL-523 Food Effect and Proton Pump Inhibitor Study
Hutchmed
Phase 1 Completed
NCT04944771 2022-05-09
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
AstraZeneca
Phase 1 Completed
NCT04564040 2020-12-29
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
AstraZeneca
Phase 1 Completed
NCT04254471 2020-02-05
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Haihe Biopharma Co., Ltd.
Phase 2/3 Unknown
NCT03260179 2017-08-24
Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
Haihe Biopharma Co., Ltd.
Phase 1 Unknown
NCT03117101 2017-04-17
Study of the AL3810 in the Treatment of Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
Phase 1 Completed